{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:49:35Z","timestamp":1792482575938,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA271410"],"award-info":[{"award-number":["U01CA271410"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA271410"],"award-info":[{"award-number":["U01CA271410"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA271410"],"award-info":[{"award-number":["U01CA271410"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA271410"],"award-info":[{"award-number":["U01CA271410"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018866","name":"Paula and Rodger Riney Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018866","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Gain or amplification of chromosome 1q (+1q) is a common genomic alteration occurring in the plasma cells in nearly 40% of multiple myeloma patients. Although it is associated with inferior outcomes and is more common in the relapsed or refractory stages, the impact of +1q at the proteomic level remains unclear. Here, we studied enriched CD138+ plasma cells in newly diagnosed multiple myeloma to uncover molecular alterations associated with +1q. Differential expression analysis revealed significantly increased expression of over 100 proteins encoded by the 1q region, indicating a potential gene dosage effect. Pathway enrichment analysis identified enrichment of cell cycle proteins such as CDK1, MCM complex, CHEK2, PSME3 and NEK7 in cases with +1q gain. Further, protein-protein interaction network analysis showed enrichment of MYC transcriptional targets in +1q cases, including increased expression of TIPRL that is encoded on 1q24. In agreement with these findings, increased\n                    <jats:italic>TIPRL<\/jats:italic>\n                    transcript expression was correlated with +1q across different cytogenetic subgroups in the CoMMpass dataset. Further, high\n                    <jats:italic>TIPRL<\/jats:italic>\n                    expression was associated with poor prognosis in patients from the hyperdiploidy subgroup. Overall, this study highlights the role of proteomics in understanding molecular events associated with chromosomal alterations in MM and identifying potential targets for further functional analysis.\n                  <\/jats:p>","DOI":"10.1038\/s41698-026-01364-7","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T08:49:28Z","timestamp":1776156568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Proteomic profiling revealed unique disease biology associated with 1q abnormalities in multiple myeloma"],"prefix":"10.1038","volume":"10","author":[{"given":"Kiran K.","family":"Mangalaparthi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel-Sean","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Erin","family":"Wiedmeier-Nutor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partho","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Staub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firdous A.","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb K.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg J.","family":"Ahmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Braggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard K.","family":"Kandasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhilesh","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"1364_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","volume":"15","author":"SK Kumar","year":"2018","unstructured":"Kumar, S. K. & Rajkumar, S. V. The multiple myelomas - current concepts in cytogenetic classification and therapy. Nat. Rev. Clin. Oncol. 15, 409\u2013421 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1364_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00474-8","volume":"11","author":"TM Schmidt","year":"2021","unstructured":"Schmidt, T. M., Fonseca, R. & Usmani, S. Z. Chromosome 1q21 abnormalities in multiple myeloma. Blood Cancer J. 11, 83 (2021).","journal-title":"Blood Cancer J."},{"key":"1364_CR3","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","volume":"108","author":"I Hanamura","year":"2006","unstructured":"Hanamura, I. et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 108, 1724\u20131732 (2006).","journal-title":"Blood"},{"key":"1364_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/ajh.26391","volume":"97","author":"HY Audil","year":"2022","unstructured":"Audil, H. Y. et al. Prognostic significance of acquired 1q22 gain in multiple myeloma. Am. J. Hematol. 97, 52\u201359 (2022).","journal-title":"Am. J. Hematol."},{"key":"1364_CR5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/leu.2017.179","volume":"32","author":"V Shah","year":"2018","unstructured":"Shah, V. et al. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. Leukemia 32, 102\u2013110 (2018).","journal-title":"Leukemia"},{"key":"1364_CR6","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1182\/bloodadvances.2020002218","volume":"4","author":"N Abdallah","year":"2020","unstructured":"Abdallah, N. et al. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Adv. 4, 3509\u20133519 (2020).","journal-title":"Blood Adv."},{"key":"1364_CR7","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar, S. V. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 99, 1802\u20131824 (2024).","journal-title":"Am. J. Hematol."},{"key":"1364_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0254-0","volume":"9","author":"TM Schmidt","year":"2019","unstructured":"Schmidt, T. M. et al. Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood Cancer J. 9, 94 (2019).","journal-title":"Blood Cancer J."},{"key":"1364_CR9","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1080\/17474086.2021.1983427","volume":"14","author":"K Bisht","year":"2021","unstructured":"Bisht, K. et al. Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies. Expert Rev. Hematol. 14, 1099\u20131114 (2021).","journal-title":"Expert Rev. Hematol."},{"key":"1364_CR10","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1182\/blood-2006-07-038703","volume":"109","author":"F Zhan","year":"2007","unstructured":"Zhan, F. et al. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood 109, 4995\u20135001 (2007).","journal-title":"Blood"},{"key":"1364_CR11","doi-asserted-by":"publisher","first-page":"5351","DOI":"10.1158\/0008-5472.CAN-14-0994","volume":"74","author":"JJ Zhao","year":"2014","unstructured":"Zhao, J. J. & Carrasco, R. D. Crosstalk between microRNA30a\/b\/c\/d\/e-5p and the canonical Wnt pathway: implications for multiple myeloma therapy. Cancer Res. 74, 5351\u20135358 (2014).","journal-title":"Cancer Res."},{"key":"1364_CR12","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1182\/blood-2016-03-704908","volume":"128","author":"JN Gong","year":"2016","unstructured":"Gong, J. N. et al. Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. Blood 128, 1834\u20131844 (2016).","journal-title":"Blood"},{"key":"1364_CR13","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/s43018-024-00784-3","volume":"5","author":"E Ramberger","year":"2024","unstructured":"Ramberger, E. et al. The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities. Nat. Cancer 5, 1267\u20131284 (2024).","journal-title":"Nat. Cancer"},{"key":"1364_CR14","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.3324\/haematol.2019.221176","volume":"105","author":"PJ Teoh","year":"2020","unstructured":"Teoh, P. J., Chung, T. H., Chng, P. Y. Z., Toh, S. H. M. & Chng, W. J. IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification. Haematologica 105, 1391\u20131404 (2020).","journal-title":"Haematologica"},{"key":"1364_CR15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ccell.2017.05.011","volume":"32","author":"M Marchesini","year":"2017","unstructured":"Marchesini, M. et al. ILF2 is a regulator of RNA splicing and DNA damage response in 1q21-amplified multiple myeloma. Cancer Cell 32, 88\u2013100 e106 (2017).","journal-title":"Cancer Cell"},{"key":"1364_CR16","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1182\/blood-2015-07-659151","volume":"127","author":"A Tagde","year":"2016","unstructured":"Tagde, A. et al. MUC1-C drives MYC in multiple myeloma. Blood 127, 2587\u20132597 (2016).","journal-title":"Blood"},{"key":"1364_CR17","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","volume":"109","author":"JD Shaughnessy Jr.","year":"2007","unstructured":"Shaughnessy, J. D. Jr. et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109, 2276\u20132284 (2007).","journal-title":"Blood"},{"key":"1364_CR18","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1038\/leu.2012.127","volume":"26","author":"R Kuiper","year":"2012","unstructured":"Kuiper, R. et al. A gene expression signature for high-risk multiple myeloma. Leukemia 26, 2406\u20132413 (2012).","journal-title":"Leukemia"},{"key":"1364_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30342-3","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y., Chen, F., Chandrashekar, D. S., Varambally, S. & Creighton, C. J. Proteogenomic characterization of 2002 human cancers reveals pan-cancer molecular subtypes and associated pathways. Nat. Commun. 13, 2669 (2022).","journal-title":"Nat. Commun."},{"key":"1364_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48327-9","volume":"15","author":"TS Johnson","year":"2024","unstructured":"Johnson, T. S. et al. 1q amplification and PHF19 expressing high-risk cells are associated with relapsed\/refractory multiple myeloma. Nat. Commun. 15, 4144 (2024).","journal-title":"Nat. Commun."},{"key":"1364_CR21","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","volume":"106","author":"PL Bergsagel","year":"2005","unstructured":"Bergsagel, P. L. et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106, 296\u2013303 (2005).","journal-title":"Blood"},{"key":"1364_CR22","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1038\/leu.2013.12","volume":"27","author":"MF Kaiser","year":"2013","unstructured":"Kaiser, M. F. et al. A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR. Leukemia 27, 1754\u20131757 (2013).","journal-title":"Leukemia"},{"key":"1364_CR23","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1158\/1538-7445.AM2016-1195","volume":"76","author":"T Lewis","year":"2016","unstructured":"Lewis, T. et al. A novel humanized anti-CD352 antibody-drug conjugate for the treatment of multiple myeloma. Cancer Res. 76, 1195 (2016).","journal-title":"Cancer Res."},{"key":"1364_CR24","doi-asserted-by":"publisher","first-page":"4470","DOI":"10.1182\/blood.V128.22.4470.4470","volume":"128","author":"TS Lewis","year":"2016","unstructured":"Lewis, T. S. et al. SGN-CD48A: a novel humanized anti-CD48 antibody-drug conjugate for the treatment of multiple myeloma. Blood 128, 4470 (2016).","journal-title":"Blood"},{"key":"1364_CR25","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/bjh.12689","volume":"164","author":"H Svachova","year":"2014","unstructured":"Svachova, H. et al. Nestin expression throughout multistep pathogenesis of multiple myeloma. Br. J. Haematol. 164, 701\u2013709 (2014).","journal-title":"Br. J. Haematol."},{"key":"1364_CR26","doi-asserted-by":"publisher","first-page":"6579","DOI":"10.1182\/blood-2023-184720","volume":"142","author":"H Gu","year":"2023","unstructured":"Gu, H. et al. Gain or amplification of chromosome 1q mediate multiple myeloma resistant to Xpo-1 inhibitor selinexor via transcription factor ETV3. Blood 142, 6579 (2023).","journal-title":"Blood"},{"key":"1364_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/srep26979","volume":"6","author":"X Wang","year":"2016","unstructured":"Wang, X. et al. The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells. Sci. Rep. 6, 26979 (2016).","journal-title":"Sci. Rep."},{"key":"1364_CR28","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1182\/blood-2013-05-500033","volume":"123","author":"Z Tian","year":"2014","unstructured":"Tian, Z. et al. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood 123, 706\u2013716 (2014).","journal-title":"Blood"},{"key":"1364_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01075-x","volume":"14","author":"M D\u2019Agostino","year":"2024","unstructured":"D\u2019Agostino, M. et al. Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells. Blood Cancer J. 14, 94 (2024).","journal-title":"Blood Cancer J."},{"key":"1364_CR30","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.bbamcr.2019.01.010","volume":"1866","author":"M Keil","year":"2019","unstructured":"Keil, M. et al. Loss of Peter Pan protein is associated with cell cycle defects and apoptotic events. Biochim Biophys. Acta Mol. Cell Res. 1866, 882\u2013895 (2019).","journal-title":"Biochim Biophys. Acta Mol. Cell Res."},{"key":"1364_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.1006936","volume":"13","author":"J Sun","year":"2022","unstructured":"Sun, J. et al. Research progress on the relationship between the TOR signaling pathway regulator, epigenetics, and tumor development. Front Genet 13, 1006936 (2022).","journal-title":"Front Genet"},{"key":"1364_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar, S. K. et al. Multiple myeloma. Nat. Rev. Dis. Prim. 3, 17046 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1364_CR33","first-page":"2950","volume":"12","author":"S Bal","year":"2022","unstructured":"Bal, S. et al. Multiple myeloma with t(11;14): unique biology and evolving landscape. Am. J. Cancer Res. 12, 2950\u20132965 (2022).","journal-title":"Am. J. Cancer Res."},{"key":"1364_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.9","volume":"3","author":"F Mirabella","year":"2013","unstructured":"Mirabella, F. et al. MMSET is the key molecular target in t(4;14) myeloma. Blood Cancer J. 3, e114 (2013).","journal-title":"Blood Cancer J."},{"key":"1364_CR35","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.molcel.2011.08.042","volume":"44","author":"AJ Kuo","year":"2011","unstructured":"Kuo, A. J. et al. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol. Cell 44, 609\u2013620 (2011).","journal-title":"Mol. Cell"},{"key":"1364_CR36","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1182\/blood-2018-02-832576","volume":"132","author":"PJ Teoh","year":"2018","unstructured":"Teoh, P. J. et al. Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis. Blood 132, 1304\u20131317 (2018).","journal-title":"Blood"},{"key":"1364_CR37","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.1002\/cam4.1596","volume":"7","author":"C Wu","year":"2018","unstructured":"Wu, C. et al. ARNT\/HIF-1beta links high-risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myeloma. Cancer Med. 7, 3899\u20133911 (2018).","journal-title":"Cancer Med."},{"key":"1364_CR38","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/ni.2527","volume":"14","author":"V Peperzak","year":"2013","unstructured":"Peperzak, V. et al. Mcl-1 is essential for the survival of plasma cells. Nat. Immunol. 14, 290\u2013297 (2013).","journal-title":"Nat. Immunol."},{"key":"1364_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01890-w","volume":"8","author":"E Lazzari","year":"2017","unstructured":"Lazzari, E. et al. Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma. Nat. Commun. 8, 1922 (2017).","journal-title":"Nat. Commun."},{"key":"1364_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188562","volume":"1876","author":"PP Gao","year":"2021","unstructured":"Gao, P. P. et al. The emerging roles of dual-specificity phosphatases and their specific characteristics in human cancer. Biochim. Biophys. Acta Rev. Cancer 1876, 188562 (2021).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"1364_CR41","doi-asserted-by":"publisher","unstructured":"Abdusamad, M. et al. DUSP12 promotes cell cycle progression and protects cells from cell death by regulating ZPR9. bioRxiv https:\/\/doi.org\/10.1101\/2025.01.13.632830 (2025).","DOI":"10.1101\/2025.01.13.632830"},{"key":"1364_CR42","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41388-018-0438-2","volume":"38","author":"M Sarwar","year":"2019","unstructured":"Sarwar, M. et al. The role of PIP5K1alpha\/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1alpha inhibitor. Oncogene 38, 375\u2013389 (2019).","journal-title":"Oncogene"},{"key":"1364_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.798590","volume":"10","author":"T Wang","year":"2022","unstructured":"Wang, T. et al. PIP5K1alpha is required for promoting tumor progression in castration-resistant prostate cancer. Front. Cell Dev. Biol. 10, 798590 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"1364_CR44","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1101\/gad.327056.119","volume":"33","author":"N Venkateswaran","year":"2019","unstructured":"Venkateswaran, N. et al. MYC promotes tryptophan uptake and metabolism by the kynurenine pathway in colon cancer. Genes Dev. 33, 1236\u20131251 (2019).","journal-title":"Genes Dev."},{"key":"1364_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-67105-3","volume":"10","author":"WI Gonsalves","year":"2020","unstructured":"Gonsalves, W. I. et al. Metabolomic and lipidomic profiling of bone marrow plasma differentiates patients with monoclonal gammopathy of undetermined significance from multiple myeloma. Sci. Rep. 10, 10250 (2020).","journal-title":"Sci. Rep."},{"key":"1364_CR46","doi-asserted-by":"publisher","first-page":"6479","DOI":"10.1158\/1078-0432.CCR-20-4366","volume":"27","author":"B Ziccheddu","year":"2021","unstructured":"Ziccheddu, B. et al. Functional impact of genomic complexity on the transcriptome of multiple myeloma. Clin. Cancer Res. 27, 6479\u20136490 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1364_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-017-0081-z","volume":"5","author":"W Zhang","year":"2017","unstructured":"Zhang, W. & Xu, J. DNA methyltransferases and their roles in tumorigenesis. Biomark. Res. 5, 1 (2017).","journal-title":"Biomark. Res."},{"key":"1364_CR48","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.3892\/ol.2014.2481","volume":"8","author":"W Zhou","year":"2014","unstructured":"Zhou, W., Chen, H., Hong, X., Niu, X. & Lu, Q. Knockdown of DNA methyltransferase-1 inhibits proliferation and derepresses tumor suppressor genes in myeloma cells. Oncol. Lett. 8, 2130\u20132134 (2014).","journal-title":"Oncol. Lett."},{"key":"1364_CR49","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40164-024-00477-8","volume":"13","author":"P Zhao","year":"2024","unstructured":"Zhao, P. et al. METTL1 mediated tRNA m(7)G modification promotes leukaemogenesis of AML via tRNA regulated translational control. Exp. Hematol. Oncol. 13, 8 (2024).","journal-title":"Exp. Hematol. Oncol."},{"key":"1364_CR50","doi-asserted-by":"publisher","unstructured":"Rizzieri, D., Paul, B. & Kang, Y. Metabolic alterations and the potential for targeting metabolic pathways in the treatment of multiple myeloma. J. Cancer Metastasis Treat. 5 https:\/\/doi.org\/10.20517\/2394-4722.2019.05 (2019).","DOI":"10.20517\/2394-4722.2019.05"},{"key":"1364_CR51","doi-asserted-by":"publisher","unstructured":"Jun, S. Y. et al. The human TOR signaling regulator is the key indicator of liver cancer patients\u2019 overall survival: TIPRL\/LC3\/CD133\/CD44 as potential biomarkers for early liver cancers. Cancers 13, https:\/\/doi.org\/10.3390\/cancers13122925 (2021).","DOI":"10.3390\/cancers13122925"},{"key":"1364_CR52","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s13402-023-00895-6","volume":"47","author":"C Cokelaere","year":"2024","unstructured":"Cokelaere, C. et al. TIPRL1 and its ATM-dependent phosphorylation promote radiotherapy resistance in head and neck cancer. Cell Oncol. 47, 793\u2013818 (2024).","journal-title":"Cell Oncol."},{"key":"1364_CR53","first-page":"1925","volume":"19","author":"X Xu","year":"2020","unstructured":"Xu, X. et al. Knockdown of TOR signaling pathway regulator suppresses cell migration and invasion in non-small cell lung cancer via the regulation of epithelial-to-mesenchymal transition. Exp. Ther. Med. 19, 1925\u20131932 (2020).","journal-title":"Exp. Ther. Med."},{"key":"1364_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2022.100279","volume":"21","author":"P Skowronek","year":"2022","unstructured":"Skowronek, P. et al. Rapid and in-depth coverage of the (phospho-)proteome with deep libraries and optimal window design for dia-PASEF. Mol. Cell Proteom. 21, 100279 (2022).","journal-title":"Mol. Cell Proteom."},{"key":"1364_CR55","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nmeth.3901","volume":"13","author":"S Tyanova","year":"2016","unstructured":"Tyanova, S. et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods 13, 731\u2013740 (2016).","journal-title":"Nat. Methods"},{"key":"1364_CR56","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1364_CR57","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/pro.3978","volume":"30","author":"R Oughtred","year":"2021","unstructured":"Oughtred, R. et al. The BioGRID database: a comprehensive biomedical resource of curated protein, genetic, and chemical interactions. Protein Sci. 30, 187\u2013200 (2021).","journal-title":"Protein Sci."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01364-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01364-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01364-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:12:34Z","timestamp":1781568754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01364-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1364"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01364-7","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"222"}}